drugset
drugset / Trial / NCT07115368

Study of GS-1219 in Participants With HIV-1

NCT07115368 ↗

Phase 1 Terminated 4 enrolled Gilead Sciences
NaSequentialOpen-labelTreatment

Summary

This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-04 is to learn more about study drug GS-1219, safety, pharmacokinetics (PK) (how GS-1219 is absorbed, modified, distributed, and removed from the body of the participants), and antiviral activity in Participants With HIV-1.

Timeline

Start
2025-08-11
Primary completion
2025-09-19
Completion
2025-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject GS-1219 Unknown 800 mg Oral
Background ABC Unknown — Oral
Background BVY Unknown — Oral
Background DTG Unknown — Oral
Background FTC Unknown — Oral
Background Lamivudine Other / unclassified — Oral
Background TAF Unknown — Oral
Background TDF Unknown — Oral

Indications

HIV infectious disease